STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on tough lung cancer
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sapanisertib and osimertinib, for people with advanced non-small cell lung cancer. The cancer must have a specific genetic change (EGFR mutation) and has gotten worse after treatment with a standard targeted drug. …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
Early trial tests drug combo to halt advanced cancer growth
Disease control OngoingThis early-stage study aims to find the safest and most effective dose of two oral medications, ceritinib and everolimus, when used together. It involves adults with advanced solid tumors or a specific type of lung cancer (ALK-positive non-small cell lung cancer) that has spread …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
New Heat-and-Zap combo fights spine tumors
Disease control OngoingThis study is testing whether using two treatments together works better than one to control cancer that has spread to the spine and is at risk of pressing on the spinal cord. Doctors combine a heat treatment (thermal ablation) that destroys tumor cells with a very precise, high-…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Double attack on lung cancer: radiation and immune drug tested
Disease control OngoingThis study is testing whether combining a targeted form of radiation therapy with an immunotherapy drug (pembrolizumab) is safe and more effective than the drug alone for patients with advanced non-small cell lung cancer that has spread. The goal is to see if the radiation helps …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Double-Duty treatment: can radiation boost cancer immunotherapy?
Disease control OngoingThis study is testing whether adding radiation therapy to two immunotherapy drugs helps control advanced lung and colorectal cancer better than the drugs alone. It enrolled 110 patients whose cancer had spread and had stopped responding to prior treatments. The main goals are to …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists test new drug duo to starve and stop advanced cancers
Disease control OngoingThis study is testing whether taking two oral drugs, cediranib and olaparib, together can help control advanced cancers that have spread or cannot be surgically removed. It is for adults with specific types of advanced lung, breast, or pancreatic cancer who have already tried at …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New combo attack on Tough-to-Treat lung cancer
Disease control OngoingThis study is testing if combining two drugs, trametinib and docetaxel, can help control advanced lung cancer that has a specific genetic change called a KRAS mutation. It is for people whose cancer has continued to grow despite one or two prior treatments. The goal is to see if …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New drug duo tested to halt lung Cancer's spread
Disease control OngoingThis study tested whether combining two targeted drugs works better than either drug alone to control advanced non-small cell lung cancer that has worsened after initial chemotherapy. It involved 125 patients whose tumors lack a specific genetic marker (EGFR mutation). The goal w…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC